cis-4-Phenyl-cyclohexylamin | 5992-23-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: cis-4-Phenyl-cyclohexylamin
• 英文别名: cis-4-phenylcyclohexan-1-amine；4-phenyl-cyclohexyl-1-amine；cis-4-phenylcyclohexylamine；cis-4-Phenylcyclohexylamin；4c-Phenyl-cyclohexylamin
• CAS: 5992-23-4
• 化学式: C₁₂H₁₇N
• 分子量: 175.274
• InChiKey: SJISCEAZUHNOMD-TXEJJXNPSA-N

物化性质

• 沸点：
  278.6±29.0 °C(Predicted)
• 密度：
  0.983±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.67
• 重原子数：
  13.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.02
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  cis-4-Phenyl-cyclohexylamin 在 吡啶 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 生成 trans-N-Butyl-N-butyryl-4-phenyl-cyclohexylamin
  参考文献：
  名称：

  Cantarelli; Carissimi; D'Ambrosio, Farmaco, Edizione Scientifica, 1970, vol. 25, # 4, p. 248 - 294

  摘要：

  DOI：
• 作为产物：
  描述：

  (1s,4s)-N-benzhydryl-4-phenylcyclohexan-1-amine 在 palladium on activated charcoal 、 氢气 、 溶剂黄146 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 3.0h， 以88%的产率得到cis-4-Phenyl-cyclohexylamin
  参考文献：
  名称：

  Discovery and synthesis of tetrahydropyrimidinedione-4-carboxamides as endothelial lipase inhibitors

  摘要：

  Endothelial lipase (EL) inhibitors have been shown to elevate HDL-C levels in pre-clinical murine models and have potential benefit in prevention and treatment of cardiovascular diseases. Modification of the 1-ethyl-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one (DHP) lead, 1, led to the discovery of a series of potent tetra- hydropyrimidinedione (THP) EL inhibitors. Synthesis and SAR studies including modification of the amide group, together with changes on the pyrimidinone core led to a series of arylcycloalkyl, indanyl, and tetralinyl substituted 5-amino or 5-hydroxypyrimidinedione-4-carboxamides. Several compounds were advanced to PK evaluation. Among them, compound 4a was one of the most potent with measurable ELHDL hSerum potency and compound 3g demonstrated the best overall pharmacokinetic parameters.

  DOI：

  10.1016/j.bmcl.2018.10.022

文献信息

• Reductive Amination of Ketonic Compounds Catalyzed by Cp*Ir(III) Complexes Bearing a Picolinamidato Ligand
  作者：Kouichi Tanaka、Takashi Miki、Kunihiko Murata、Ayumi Yamaguchi、Yoshihito Kayaki、Shigeki Kuwata、Takao Ikariya、Masahito Watanabe

  DOI：10.1021/acs.joc.9b01565

  日期：2019.9.6

  Cp*Ir complexes bearing a 2-picolinamide moiety serve as effective catalysts for the direct reductive amination of ketonic compounds to give primary amines under transfer hydrogenation conditions using ammonium formate as both the nitrogen and hydrogen source. The clean and operationally simple transformation proceeds with a substrate to catalyst molar ratio (S/C) of up to 20,000 at relatively low

  带有2-吡啶甲酸酰胺部分的Cp * Ir配合物可作为有效的催化剂，用于在酮的转移氢化条件下，使用甲酸铵作为氮源和氢源，对酮类化合物进行直接还原胺化，从而生成伯胺。清洁且操作简单的转化过程是在相对较低的温度下以高达20,000的底物与催化剂的摩尔比（S / C）进行的，并且对伯胺表现出出色的化学选择性。
• METHOD FOR PRODUCING NOVEL ORGANOMETALLIC COMPLEX AND AMINE COMPOUND
  申请人：KANTO KAGAKU KABUSHIKI KAISHA

  公开号：US20160060282A1

  公开（公告）日：2016-03-03

  The purpose of the invention is to provide a novel organometallic compound that can be utilized as a catalyst having high generality, high activity, and excellent functional group selectivity. The invention pertains to a novel organometallic compound represented by general formula (1) that catalyzes a reductive amination reaction.

  该发明的目的是提供一种新型有机金属化合物，可用作具有高普适性、高活性和优异官能团选择性的催化剂。该发明涉及一种由一般式（1）表示的新型有机金属化合物，其催化还原胺化反应。
• [EN] 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZOLO[4,3-A]PYRIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2012062750A1

  公开（公告）日：2012-05-18

  The present invention relates to novel triazolo [4,3-a]pyridine derivatives of Formula (I), wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及式(I)的新三唑[4,3-a]吡啶衍生物，其中所有基团均如权利要求中所定义。根据发明的化合物是代谢型谷氨酸受体2型("mGluR2")的正变构调节剂，用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及mGluR2亚型的代谢型受体的疾病。本发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的方法，以及使用这些化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病。
• [EN] QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE<br/>[FR] INHIBITEURS QUINOLÉINONE CARBOXAMIDE DE LIPASE ENDOTHÉLIALE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013048942A1

  公开（公告）日：2013-04-04

  The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

  本发明提供了如规范中定义的Formula (I)的化合物，以及包含任何此类新化合物的组合物。这些化合物是内皮脂酶抑制剂，可用作药物。
• [EN] PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE<br/>[FR] INHIBITEURS À BASE DE PYRIMIDINEDIONECARBOXAMIDE DE LIPASE ENDOTHÉLIALE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013151877A1

  公开（公告）日：2013-10-10

  The present invention provides compounds of Formula (I), as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

  本发明提供了如规范中定义的Formula (I)的化合物，以及包含任何此类新化合物的组合物。这些化合物是内皮脂酶抑制剂，可用作药物。